See more : Whitehaven Coal Limited (WHC.AX) Income Statement Analysis – Financial Results
Complete financial analysis of IO Biotech, Inc. (IOBT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IO Biotech, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Kimbell Royalty Partners, LP (KRP) Income Statement Analysis – Financial Results
- China Construction Bank Corporation (CICHF) Income Statement Analysis – Financial Results
- BOCOM International Holdings Company Limited (3329.HK) Income Statement Analysis – Financial Results
- Hudbay Minerals Inc. (HBM) Income Statement Analysis – Financial Results
- Blue Vision A/S (BLVIS-A.CO) Income Statement Analysis – Financial Results
IO Biotech, Inc. (IOBT)
About IO Biotech, Inc.
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 756.00K | 540.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -756.00K | -540.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 67.83M | 46.99M | 30.15M | 8.46M | 7.94M |
| General & Administrative | 23.61M | 24.44M | 11.08M | 1.68M | 1.98M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.61M | 24.44M | 11.08M | 1.68M | 1.98M |
| Other Expenses | 0.00 | 0.00 | -26.54M | -1.99M | -781.00K |
| Operating Expenses | 91.44M | 71.42M | 41.23M | 10.15M | 9.91M |
| Cost & Expenses | 91.44M | 71.42M | 41.23M | 10.15M | 9.91M |
| Interest Income | 5.88M | 1.41M | 361.00 | 26.00 | 6.00 |
| Interest Expense | 0.00 | 302.00K | 361.00K | 26.00K | 6.00K |
| Depreciation & Amortization | 215.00K | 540.00K | 2.00K | 10.15M | 9.91M |
| EBITDA | -91.44M | -69.34M | -67.45M | 0.00 | -824.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -91.44M | -71.42M | -41.23M | -10.15M | -9.91M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.21M | 1.24M | -26.58M | -1.90M | -830.00K |
| Income Before Tax | -85.23M | -70.19M | -67.81M | -12.04M | -10.74M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 852.00K | 1.27M | 68.00K | 26.00K | 6.00K |
| Net Income | -86.08M | -71.46M | -67.88M | -12.07M | -10.75M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.98 | -2.48 | -2.36 | -0.42 | -0.37 |
| EPS Diluted | -1.98 | -2.48 | -2.36 | -0.42 | -0.37 |
| Weighted Avg Shares Out | 43.54M | 28.82M | 28.82M | 28.82M | 28.82M |
| Weighted Avg Shares Out (Dil) | 43.54M | 28.82M | 28.82M | 28.82M | 28.82M |
IO Biotech to Present at the Jefferies Healthcare Conference
IO Biotech to Participate in March 2023 Investor Conferences
IO Biotech to Present at 42nd Annual Cowen Healthcare Conference
IO Biotech (IOBT) Stock: $21 Price Target From Morgan Stanley
Source: https://incomestatements.info
Category: Stock Reports